Why There Is No Cookbook Approach to Palliative Care: Implications of the P450 Enzyme System

Kim K. Kuebler, MN, RN, ANP-CS, James Varga, MBA, PharmBS, and Ronald A. Mihelic, PharmD

A plethora of literature describes the impact of the P450 enzyme system, but this information is limited regarding its relevancy to nursing practice. However, oncology nurses providing palliative symptom management must have a working knowledge of the P450 enzyme system to recognize the variability that exists among individual medication reactions or why a “cookbook approach” to symptom management is not always effective and appropriate. This article describes the variations associated with medication metabolism with reference to ethnic differences. Having a basic understanding of the P450 enzyme system and, more specifically, the CYP2D6 influence on the metabolism of common medications used in palliative symptom management can help to prevent medication toxicity or underdosing, which interferes with patients’ quality of life.

Key Words: cytochrome P-450 enzyme system, pharmacokinetics, palliative care

Drug Interactions

Patients with advanced cancer receive an average of five or more medications at any given time for symptom relief. Polypharmacy increases the risk of adverse drug interactions (Davis & Homsi, 2001). Drug interactions generally fall into two categories: pharmacodynamic or pharmacokinetic.

Pharmacodynamic interactions are related to a drug’s mechanism of action on physiologic function. Drug interactions of this type frequently involve competition at a specific receptor site or neuronal pathway. Drug metabolism may remain unaltered. For example, a common pharmacodynamic drug-to-drug interaction may involve the concomitant use of an antimuscarinic drug (anticholinergic) and a prokinetic drug (antacid). When these drugs are prescribed together, the final pathway for the prokinetic drug (e.g., metoclopramide) is cholinergic. A drug with anticholinergic properties (e.g., diphenhydramine) may block the same receptor or pathway of metoclopramide; ultimately, this competition will diminish the

Submitted January 2003. Accepted for publication April 7, 2003. (Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Society.)

Digital Object Identifier: 10.1188/03.CJON.569-572